Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (1)：
2022 - 2025 Assessment of cerebrospinal fluid ctDNA for the development of systemic therapy for brain metastases and leptomeningea disease of HER2-negative breast cancer
Papers (44)：
Miyazaki N, Iwasaki T, Sakai H, et al. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Curr Med Res Opin. 2024
Terada Mitsuo, Ito Aki, Kikawa Yuichiro, Koizumi Kei, Naito Yoichi, Shimoi Tatsunori, Ishihara Mikiya, Yamanaka Takashi, Ozaki Yukinori, Hara Fumikata, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast cancer (Tokyo, Japan). 2023. 30. 6
Hiroko Masuda, Yuko Tanabe, Hitomi Sakai, Koji Matsumoto, Akihiko Shimomura, Mihoko Doi, Yasuo Miyoshi, Masato Takahashi, Yasuaki Sagara, Shinya Tokunaga, et al. Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). Breast (Edinburgh, Scotland). 2023. 71. 22-28
Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). Journal for ImmunoTherapy of Cancer. 2023. 11. 9. e007126-e007126
Hitomi Sakai, et al. Protocol for a Prospective Cohort Study to Evaluate Changes in Sexuality in Patients With Primary Cervical Cancer Using Patient-Reported Outcomes (JGOG9004, SARAH Study), and Our Approaches to Solving the Unmet Needs of Patients With Gynecological Cancer. 2023. 12. 2. 59-64
鶴谷純司, 酒井瞳. The mechanisms of resistance against ADCs, to overcome. 月刊腫瘍内科. 2023. 32. 5
Meiko Nishimura, Takahiro Kogawa, Yuko Akaishi, Misato Ogata, Jun Masuda, Mitsuo Terada, Hitomi Sakai, Kazuki Nozawa, Sasagu Kurozumi, Takamichi Yokoe, et al. Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients. CANCER RESEARCH. 2022. 82. 4
Yoshio Itani, Hitomi Sakai, Mikiko Asai-Sato, Shinya Sato, Masayuki Futagami, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Tetsutaro Hamano, Yoshio Yoshida. A post-hoc study of relative dose intensity in elderly patients with advanced ovarian cancer (JGOG3016-A3). JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
Roles of Probiotics, Trimebutine Maleate, and Loperamide in Abemaciclib-Induced Diarrhea (WJOG11318B, MERMAID)
(JSMO2024 2024)
WJOG (West Japan Oncology Group)Breast Cancer Consensus Meeting 2023
(JSMO2024 2024)
Toxicity of combination therapy with nivolumab and abemaciclib in HR-positive metastatic breast cancer: WJOG11418B
(JSMO2024 2024)
A randomized, double-blind, placebo-controlled study of olanzapine for CINV during T-DXd in HER2 positive metastatic breast cancer patients: WJOG14320B (ERICA)
(GBCC 2023)
HER2+ mBC患者を対象としたT-DXd投与中のCINVに対するオランザピン投与の第II相試験 WJOG14320B(ERICA)(Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA))
(日本乳癌学会総会プログラム抄録集 2022)
